These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 22343624)

  • 21. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
    Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reappraisal of the options for colorectal cancer screening in England.
    Whyte S; Chilcott J; Halloran S
    Colorectal Dis; 2012 Sep; 14(9):e547-61. PubMed ID: 22390210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
    Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England.
    Benton SC; Piggott C; Blyuss O; Li SJ; Mathews C; Carroll M; Duffy S
    J Med Screen; 2021 Dec; 28(4):426-432. PubMed ID: 33983066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of once-only flexible sigmoidoscopy screening on the outcomes of subsequent faecal occult blood test screening.
    Brown JP; Wooldrage K; Kralj-Hans I; Wright S; Cross AJ; Atkin WS
    J Med Screen; 2019 Mar; 26(1):11-18. PubMed ID: 30282520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals.
    Holme Ø; Bretthauer M; Fretheim A; Odgaard-Jensen J; Hoff G
    Cochrane Database Syst Rev; 2013 Oct; 2013(9):CD009259. PubMed ID: 24085634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline.
    Helsingen LM; Vandvik PO; Jodal HC; Agoritsas T; Lytvyn L; Anderson JC; Auer R; Murphy SB; Almadi MA; Corley DA; Quinlan C; Fuchs JM; McKinnon A; Qaseem A; Heen AF; Siemieniuk RAC; Kalager M; Usher-Smith JA; Lansdorp-Vogelaar I; Bretthauer M; Guyatt G
    BMJ; 2019 Oct; 367():l5515. PubMed ID: 31578196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare.
    Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM
    Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
    Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
    Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for colorectal cancer: spoiled for choice?
    Sarfati D; Shaw C; McLeod M; Blakely T; Bissett I
    N Z Med J; 2016 Aug; 129(1440):120-8. PubMed ID: 27538046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
    Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
    Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
    Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
    BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.